Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(4.27)
# 1,409
Out of 4,491 analysts
118
Total ratings
38.9%
Success rate
15.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Initiated Coverage: Buy | n/a | $9.51 | - | 1 | Jun 24, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $101 | $54.57 | +85.10% | 10 | Jun 7, 2026 | |
| STTK Shattuck Labs | Initiated Coverage: Buy | n/a | $6.88 | - | 1 | Apr 27, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | n/a | $45.61 | - | 4 | Mar 6, 2026 | |
| MANE Veradermics | Initiated Coverage: Buy | n/a | $118.25 | - | 1 | Mar 1, 2026 | |
| TVTX Travere Therapeutics | Reiterated: Buy | n/a | $57.10 | - | 7 | Feb 20, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | n/a | $18.82 | - | 9 | Dec 4, 2025 | |
| EVMN Evommune | Initiated Coverage: Buy | n/a | $13.25 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | n/a | $546.51 | - | 4 | Nov 4, 2025 | |
| ACRS Aclaris Therapeutics | Reiterated: Buy | n/a | $5.55 | - | 2 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.47 | - | 6 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6431 | - | 10 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $19.21 | - | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.37 | n/a | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $36.09 | n/a | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $85.59 | n/a | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $56.70 | n/a | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.38 | n/a | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $2.8 | $2.94 | n/a | 10 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.66 | n/a | 2 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $3.5 | $2.02 | n/a | 3 | Jan 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $23 | $4.02 | n/a | 8 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $62 | $11.87 | n/a | 8 | Oct 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $27.99 | n/a | 8 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 | $2.13 | n/a | 8 | Aug 5, 2021 |
Silence Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $9.51
Upside: -
Structure Therapeutics
Jun 7, 2026
Maintained: Buy
Price Target: $101
Current: $54.57
Upside: +85.10%
Shattuck Labs
Apr 27, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $6.88
Upside: -
Zealand Pharma A/S
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $45.61
Upside: -
Veradermics
Mar 1, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $118.25
Upside: -
Travere Therapeutics
Feb 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $57.10
Upside: -
MoonLake Immunotherapeutics
Dec 4, 2025
Maintained: Buy
Price Target: n/a
Current: $18.82
Upside: -
Evommune
Dec 1, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $13.25
Upside: -
Madrigal Pharmaceuticals
Nov 4, 2025
Upgraded: Buy
Price Target: n/a
Current: $546.51
Upside: -
Aclaris Therapeutics
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.55
Upside: -
Sep 26, 2025
Reiterated: Buy
Price Target: n/a
Current: $10.47
Upside: -
Sep 15, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.6431
Upside: -
Aug 15, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $19.21
Upside: -
Jul 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.37
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $36.09
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $85.59
Upside: n/a
Mar 3, 2025
Reiterated: Buy
Price Target: n/a
Current: $56.70
Upside: n/a
Jan 21, 2025
Downgraded: Hold
Price Target: n/a
Current: $11.38
Upside: n/a
Aug 11, 2023
Maintained: Buy
Price Target: $14 → $2.8
Current: $2.94
Upside: n/a
Mar 17, 2023
Rated: Hold
Price Target: n/a
Current: $6.66
Upside: n/a
Jan 10, 2023
Maintained: Buy
Price Target: $5 → $3.5
Current: $2.02
Upside: n/a
Sep 12, 2022
Maintained: Buy
Price Target: $27 → $23
Current: $4.02
Upside: n/a
Oct 18, 2021
Maintained: Buy
Price Target: $58 → $62
Current: $11.87
Upside: n/a
Sep 21, 2021
Maintained: Buy
Price Target: $44
Current: $27.99
Upside: n/a
Aug 5, 2021
Maintained: Buy
Price Target: $22
Current: $2.13
Upside: n/a